(P-1079) In Vitro and in Vivo Antiviral Activity of S-892216, a Second-Generation Oral 3CL^pro Inhibitor against SARS-CoV-2

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Haruaki Nobori, PhD (he/him/his)

Manager
SHIONOGI & CO., LTD.
Toyonaka-shi, Osaka, Japan

Co-Author(s)

Sho Kawashima (he/him/his)

Resercher
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
RD

Reiko Dodo, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
YM

Yuki Maruyama, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
TH

Takayo Haruna, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
KH

Keiichiro Hirai, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
YU

Yuto Unoh, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
KN

Kenji Nakahara, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
SU

Shota Uehara, Ph.D.

SHIONOGI & CO., LTD.
Toyonaka-shi, Osaka, Japan
rw

ryosuke watari, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
tk

tomoyuki kawachi, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
yN

yuka Natsume, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
kh

katsumoto hata, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
yo

yukiko orita, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
kf

kae fujisawa, n/a

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
tm

tetsuya miyano, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
hk

hideko kaneda, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
tk

taeko kawai, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
KI

Kae Inoue, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
AH

Akane Hayashi, n/a

Shionogi TechnoAdvance Research, Co., Ltd.
Toyonaka, Osaka, Japan
TH

Takashi Hashimoto, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
KM

Kazumi Matsumoto, n/a

Shionogi TechnoAdvance Research, Co., Ltd.
Toyonaka, Osaka, Japan
KB

Kaoru Baba, n/a

Shionogi TechnoAdvance Research, Co., Ltd.
Toyonaka, Osaka, Japan
tu

taichi ueda, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
ts

takafumi sato, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
TK

Teruhisa Kato, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan
Keita Fukao, MD (he/him/his)

Director Head of Infectious Diseases 3
Shionogi&Co., Ltd.
Toyonaka, Osaka, Japan

(P-1079) In Vitro and in Vivo Antiviral Activity of S-892216, a Second-Generation Oral 3CLpro Inhibitor against SARS-CoV-2

Presenting Author(s)

Co-Author(s)

(P-1079) In Vitro and in Vivo Antiviral Activity of S-892216, a Second-Generation Oral 3CL^pro Inhibitor against SARS-CoV-2